Apolipoprotein (APO)E Genotype, Meal Fatty Acids, Postprandial Lipaemia
Effects of Meal Fatty Acid Composition on Postprandial Lipaemia in Men According to APOE Genotype
Cardiovascular disease (CVD) is the greatest cause of morbidity and mortality in the UK. Abnormalities in the concentration and/or composition of lipoproteins (the lipid carrying particles), in particular low density lipoproteins (LDL) in circulation, is one of the most important physiological defects contributing to the development of CVD.
The LDL cholesterol (LDLC) response to fatty acid change is in part mediated by the APOE genotype, with E4 individuals (25% of the UK population) being most responsive to changes in dietary fats, showing greater reductions when low levels of saturated fats or fish oils are consumed and greater increases when high levels of these fats are consumed. Therefore the aims of the present study is to understand the mechanism that regulates the higher LDLC response associated with saturated fatty acids and fish oil consumption in healthy men prospectively recruited based on their APOE genotype.
연구 개요
상태
정황
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Reading, 영국
- Department of Food and Nutritional Sciences, University of Reading
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Gender Male
- Age 18-70 years
- Body Mass Index (BMI) < 32 kg/m2
- Plasma triglycerides 1-4 mmol/l
- Plasma cholesterol < 8 mmol/l
- Glucose < 7 mmol/l
- Haemoglobin > 11 g/dl
- ApoE E3/E3, E3/E4
Exclusion Criteria:
- Blood pressure > 200/95 mmHg
- Had suffered a myocardial infraction or stroke in previous 2 years.
- Diabetes mellitus
- Liver disease
- Other endocrine disorders
- Unstable angina
- Familial hyperlipidaemia
- Any dietary restrictions or an a weight reducing diet
- On fatty acid supplements e.g. evening primrose oil or fish oils
- Vigorous exercise e.g. competitive athletes
- ApoE2/E2, apoE2/E3 and apoE2/E4
- Any other parameter on which the investigators felt an individual was unsuitable
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: High saturated fat meal
|
Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
|
|
실험적: Saturated fatty acid and fish oils meal
Equivalent to two portions of oily fish
|
Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil. The dose of fish oils was equivalent to two portions of oily fish. |
|
활성 비교기: High unsaturated fat meal
Provided a fatty acid profile representative of a typical UK diet
|
Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats.
It provided a fatty acid profile representative of a typical UK diet.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Impact of APOE genotype and dietary fat composition in plasma lipids
기간: 3 months
|
3 months
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Cardiovascular disease risk factors
기간: 3 months
|
3 months
|
공동 작업자 및 조사자
협력자
간행물 및 유용한 링크
일반 간행물
- Calabuig-Navarro MV, Jackson KG, Kemp CF, Leake DS, Walden CM, Lovegrove JA, Minihane AM. A randomized trial and novel SPR technique identifies altered lipoprotein-LDL receptor binding as a mechanism underlying elevated LDL-cholesterol in APOE4s. Sci Rep. 2017 Mar 9;7:44119. doi: 10.1038/srep44119.
- Calabuig-Navarro MV, Jackson KG, Walden CM, Minihane AM, Lovegrove JA. Apolipoprotein E genotype has a modest impact on the postprandial plasma response to meals of varying fat composition in healthy men in a randomized controlled trial. J Nutr. 2014 Nov;144(11):1775-80. doi: 10.3945/jn.114.197244. Epub 2014 Sep 17.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .